ASH News Daily - Monday, December 12, 2011 - (Page B-41)
Now Enrolling
Investigating Everolimus* in Diffuse Large B-cell Lymphoma
PILLAR-2
PIvotaL Lymphoma triAls of RAD001
Study Description
Phase III, double-blind study in poor-risk patients with diffuse large B-cell lymphoma (DLBCL) following complete response to rituximab-containing chemotherapy
Study Design†
Everolimus for 1 year
Randomize 1:1
Screen
Placebo for 1 year
†
Treatment until relapse, unacceptable toxicity, death, or discontinuation for any other reason.
Primary Endpoint
Disease-free survival
For more information
• Call 1-800-340-6843 (United States only) • Visit www.thewideprogram.com • Contact your local Novartis Medical Science Liaison
*This is an investigational study; there is no guarantee that everolimus will become commercially available for this indication.
PILLAR-2
PIvotaL Lymphoma triAls of RAD001
PR
WIDE
GRAM
Worldwide Initiative to Develop Everolimus
THE
TM
mTOR
Novartis Pharma AG CH-4002 Basel, Switzerland
©Novartis 2011
February 2011
RAD-1011242 GCT9124
Novartis Pharmaceuticals Corporation East Hanover, NJ 07936
RDGF16847_PILL2_ASH_DN_DR2.indd 1
10/14/11 10:54 AM
Table of Contents for the Digital Edition of ASH News Daily - Monday, December 12, 2011
ASH News Daily - Monday, December 12, 2011
https://www.nxtbookmedia.com